Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q3 FY2022 Earnings Presentation
26 slides from Dishman Carbogen Amcis's earnings presentation, Feb 4, 2022
Slide 1: Dishman Carbogen Amcis - Regulation 30 filing cover letter
Dishman Carbogen Amcis" Dishman Carbogen Amcis Ltd Dishman Corporate House 9 lscon-Bopal Road, Ambli, • Ahmedabad - 380058 • Gujarat, India CIN:L74900GJ2007PLC051338 +9127 1742 0102 � dishman@dishmangroup.com 181 4th February, 2022 www.imdcal.com @) To, To, Department of Corporate Services The Manag
Slide 2: Quarter ended December 31st, 2021
Quarter ended December 31st, 2021 February 2022
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING Dedicated R&D Labs, including APIS in R&D - 950+ FACILITIES Globally H
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 20,586 20,436 4,087 19,120 5,519 3,660 17,137 16,948 4,976 4,534 4,453 2,994 26.8% 24.3% 2,538 26.3% 2,744 26.5% 14.3% FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
QUARTER HIGHLIGHTS
Slide 8: Q3 FY22 Result Highlights
Q3 FY22 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 5,621 4,686 4,589 1,095 992 626 21.6% 19.5% 13.4% Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 9.4% 10.8% 6.3 608 5.4 432 982 3.6 843 0.0% 571 2 Q3FY21 Q2FY22 Q
Slide 9: 9M FY22 Result Highlights
9M FY22 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 15,717 3,094 13,825 1,857 19.7% 13.4% 9MFY21 9MFY22 9MFY21 9MFY22 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 17.2 9.6% 2,697 11.2 1,502 1,760 1.1% 149 9MFY21 9MFY22 9MFY21 9MFY22 *EBITDA excluding oth
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q3 FY22 Q3 FY21 YoY % 9M FY22 9M FY21 YoY % Income from Operations (Net) 5,620.8 4,685.6 20.0% 15,717.0 13,824.6 13.7% COGS 1,288.3 851.3 51.3% 2,997.0 3,017.60 -0.7% Employee Expenses 2,550.8 2,244.1 13.7% 7,289.0 6,531.5 11.6% Other Expenses 686.7 964.
Slide 11: Segment Wise Revenue Analysis
SEGMENT WISE REVENUE ANALYSIS Revenues – Segment wise Breakup (₹ mn) Q3 FY22 Q3 FY21 YoY % 9M FY22 9M FY21 YoY% CRAMS (% of total) 82.1% 74.1% 76.4% 75.8% CRAMS - India 396.5 200.4 97.9% 1,112.1 407.4 173.0% CRAMS - Switzerland, France & China 3,934.0 2,991.6 31.5% 9,960.4 9,278.8 7.3% CRAMS - UK 28
Slide 12: Segment Wise Revenue Break-up
SEGMENT WISE REVENUE BREAK-UP Total Operating Revenue – Q3 FY22 Total Operating Revenue – 9M FY22 CRAMS – 82.1% Marketable Molecules – 17.9% CRAMS – 76.4% Marketable Molecules – 23.6% 9.3% 6.1% 8.6% 7.8% 10.8% 8.0% 1.3% 2.1% 34.5% 46.1% 53.9% 65.5% 73.2% 72.9% CRAMS - India CRAMS - Switzerland Carbo
Slide 13: Segment-Wise Margin Analysis
SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin* % Q3 FY22 Q3 FY21 9M FY22 9M FY21 CRAMS CRAMS- India 9.1% - 7.0% - CRAMS – Switzerland, France & China 20.7% 19.2% 20.2% 19.1% CRAMS - UK 10.9% 21.4% 18.6% 18.9% Marketable Molecules Carbogen Amcis BV 30.5% 34.9% 30.4% 34.5% Others 6.3% 18.3% 7.2% 15.5% *i
Slide 14: Q3 & 9M FY22 Result Highlights
Q3 & 9M FY22 RESULT HIGHLIGHTS Net Revenue at Rs 5,620.8 mn in Q3 FY22 up by 20.0% YoY CRAMS revenue increased by 34.3% YoY primarily due to: CRAMS India revenue increased by 97.9% due to steady increase in operations from the manufacturing plants located in India. CRAMS - Switzerland, France & Chin
Slide 15: Company Overview
COMPANY OVERVIEW
Slide 16: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 17: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 18: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 19: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 20: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES § Focus is on supporting the development process from bench to market § Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 21: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 22: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY21 FY21 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 21
Slide 23: Industry Overview
Dishman Carbogen Amcis INDUSTRY
Slide 24: Top 20 Therapy Areas (US$ bn) - 2025
2025 Expected Global Spending by Therapy Areas Oncology & Immunology expected to dominate sales and grow by 9-12% CAGR through 2025 5-Yr CAGR 2021-2025 Oncologics 273 9-12% Immunology 175 9-12% Top 20 Therapy Areas (US$ bn) - 2025 Antidiabetics 148 4-7% Neurology 143 3-6% Cardiovascular 74 1-4% Anti
Slide 25: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent nearly half of global spending in 2025 and almost 60% of total spending in developed markets 59% 47% 45% 41% 37% 38% 35% 28% 29% 24% 21% 21% 17% 14% 9% 10% 2010 2015 2020 2025 Pharmerging Other Developed Global 10 Developed 24 Sourc
Slide 26: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Mr. Binay Sarda Group CFO Christensen IR Email: harshil.dalal@dishmangroup.com P: +91 22 4215 0210 Email: bsarda@christensenir.com
Dishman Carbogen Amcis — Q3 FY2022 Earnings Presentation on 6ix